ArticleJournal of general internal medicine2018

If the IMPROVE-IT Trial Was Positive, as Reported, Why Did the FDA Denied Expanded Approval for Ezetimibe and Simvastatin? An Explanation of the Tipping Point Analysis.

Emma P Deloughery et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.